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Macrolide resistance in Mycoplasma pneumoniae is 
often found in Asia but is rare elsewhere. We report the 
emergence of macrolide-resistant M. pneumoniae in Israel 
and the in vivo evolution of such resistance during the 
treatment of a 6-year-old boy with pneumonia.
M
ycoplasma pneumoniae is a leading respiratory 
pathogen in both pediatric (1,2) and adult (1,3) 
populations. Macrolides are considered the ﬁ   rst line of 
therapy and are almost the only treatment for children. 
In recent years, alarming rates of M. pneumoniae with 
macrolide resistance (<90%) have occurred in eastern Asia, 
including the People’s Republic of China, Japan, and Korea 
(2,4–7). This was initially reported in children; however, a 
surge of resistance in adults was recently reported (2,4,7). 
Macrolide-resistant M. pneumoniae has also been suggested 
to be associated with a longer course of disease (2,4).
In the Western Hemisphere, lower rates of macrolide 
resistance have been reported (<10%), however, several 
epidemics with notable complications have occurred (8–
11). We report the detection of macrolide resistance in M. 
pneumoniae in Israel. 
The Study
A previously healthy 6-year-old boy was hospitalized 
after 2 weeks with fever up to 40°C. At onset of illness, a 
diagnosis of pharyngitis was made. Streptococcus pyogenes 
was isolated from his throat, and amoxicillin was prescribed 
without any clinical response. Later, a clinical diagnosis 
of sinusitis was made, and amoxicillin-clavulanate was 
prescribed. A chest radiograph done at that time reportedly 
showed no abnormalities. Laboratory investigation before 
admission showed leukocytosis of 19,600 cells/mm3 
with 2,200 monocytes/mm3 and 7,600 neutrophils/mm3; 
L-lactate dehydrogenase (LDH) was 1,854 U/L (reference 
value up to 600 U/L). 
Ten days after the beginning of his illness, his fever 
decreased for 2 days and then reappeared, together with 
cough, resulting in hospitalization. At admission, pneumonia 
of the right middle and lower lobe was conﬁ  rmed by chest 
radiograph. Laboratory tests showed leukocytes within 
normal ranges, erythrocyte sedimentation rate (ESR) 80/h, 
and C-reactive protein (CRP) 15 mg/L (reference range up 
to 0.5 mg/L). Treatment with penicillin was started without 
clinical improvement. Azithromycin (10 mg/kg/d) was 
added on the third day. After receiving this treatment, his 
leukocytes increased to 20,000 cells/mm3 with ESR 97/h 
and CRP 22.5 mg/L. The β-lactam coverage was switched 
to cefuroxime and later to ceftriaxone because no response 
was observed. Chest ultrasound showed a small pleural 
effusion. Bronchoscopy showed thick mucus secretions; 
respiratory specimens tested were negative for respiratory 
syncytial virus, inﬂ  uenza viruses A and B, parainﬂ  uenza 
virus, human metapneumovirus, and adenovirus, as were 
results of urine tests for Legionella spp. and blood tests for 
pneumococcal antigen and cryptococcal antigen.
Throat swab specimens were collected and DNA 
extracted by boiling. Samples were positive for M. 
pneumoniae by real-time PCR based on the detection 
of a 188-nt amplicon from the 3′ region of the repeat 
RepMP4 (primers: MpP1–1217_F-GTTGAAGAACG
CCCAAGTGAA; MpP1–1292_R-CCGGTGGTTTGGAG
CAAA). The target DNA was ampliﬁ  ed by using Polymerase 
(SYBR Green) master mix (KapaTM SYBR Fast qPCR; 
Kapa Biosystems, Cape Town, South Africa), followed by 
a melt curve analysis (Rotor-Gene 6000; Corbett Research, 
Mortlake, NSW, Australia) with 1:30 polymerase activation 
at 95°C, followed by 42 cycles of 95°C for 10 s, 60°C for 
18 s, 72°C for 8 s. The assay has an analytical sensitivity of 
10 fg DNA or 1 to 3.3 genome copies.
Despite the M. pneumoniae–positive throat swab at 
admission, no clinical response was observed for treatment 
with azithromycin for 8 days. This led to the suspicion of 
macrolide-resistant M. pneumoniae. Samples were further 
analyzed for possible resistance-associated mutations 
(A2063G/C, A2064G, and A2067G) that constitute 
98% of macrolide resistance–associated mutations in 
M. pneumoniae (2). Real-time PCR of domain V region 
of the 23S rRNA gene with a high-resolution melt curve 
analysis utilizing the SYBR Green ampliﬁ  cation primers 
was used (10). The emergence of resistant mutants during 
treatment was conﬁ  rmed by sequence analysis of the whole 
region with additional PCR of a larger amplicon size (10) 
(Figure 1). This conﬁ  rmed the presence of the resistant 
A2063G mutation on the later samples.
Accordingly, on hospital day 21, treatment was 
switched to doxycycline, 4 mg/kg 2×/d for 5 days, with a 
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and the child was discharged. However, on day 33 from 
his ﬁ  rst admission, he was readmitted with fever, cough, 
and hypoxia (oxygen saturation 85%). Chest radiograph 
showed atelectasis in the right middle lobe and lingula. 
PCR of a throat swab specimen for M. pneumoniae was 
again positive. Treatment with ciproﬂ  oxacin was started 
with prompt response; hypoxia subsided gradually and 
fever normalized. The child was treated with ciproﬂ  oxacin 
for 4 weeks and fully recovered.
During January 2010–August 2010, we observed a 
surge in M. pneumoniae–associated respiratory disease (30 
cases during 8 months compared with 2 cases during 2009) 
at the Hadassah–Hebrew University Medical Centers. The 
Centers comprise 2 hospitals with a total of 1,000 beds in 
the city of Jerusalem. The Ein-Kerem campus is a tertiary 
center serving west Jerusalem, while the Mount Scopus 
campus is a secondary hospital providing primary care 
services to east Jerusalem. Samples from both hospitals are 
processed at Ein-Kerem’s clinical microbiology laboratory.  
During the survey period, 274 samples were submitted, 
of which 42 samples from 30 patients were positive for 
M. pneumoniae. Following this case, we screened all M. 
pneumoniae–positive samples for macrolide resistance. In 
9 of 30 patients tested, we found the A2063G mutation, 
which was conﬁ  rmed by sequencing. In 2 pediatric patients, 
a mixed population of both resistant (A2063G) and 
sensitive (A2063A) organisms was identiﬁ  ed (Figure 2). 
Notably, a 31-year-old woman was found to carry the 
A2063G mutation as well. No signiﬁ  cant difference was 
found in clinical parameters between the 9 patients with 
resistant and 19 patients with sensitive M. pneumoniae 
species (Table). Other than our propositus case, we did not 
observe in our sample a longer course of disease in patients 
with macrolide-resistant M. pneumoniae, as suggested in 
previous studies (6,12).
Conclusions
The observed rate of resistance in our hospital-based 
patients in the current surge of M. pneumoniae–associated 
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Figure 1. Time elapsed and chromatogram of wild-type Mycoplasma 
pneumonia strain M129 (ATCC 29342) compared with results from 
5 samples from a 6-year-old boy in Israel. The A2063G mutation 
is shown to be evolving during treatment and predominates at the 
end. 
Figure 2. Real-time PCR high-resolution melting assay. A) High-
resolution melt proﬁ  les are shown for wild-type (WT) Mycoplasma 
pneumoniae A (A2063A), macrolide resistance mutation G (A2063G) 
sample, and the mixed genotype sample in the normalized graph 
mode. B) Temperature-shifted difference graph demonstrates the 
deviations between WT, resistant, and mixed samples. The WT 
isolate has been selected to normalize the temperature shift graph 
and displays the deviation of samples from it.Macrolide Resistance in M. pneumoniae, Israel
cases is 30%. A2063G was the only resistance-associated 
mutation we found out of 4 possible mutations the assay 
we used can ﬁ   nd. This is not surprising because this 
mutation is reportedly responsible for 90.5% of resistant M. 
pneumoniae (2). As recently reported from Japan, China, 
and Germany (2,4,7), we also found resistance in an adult 
patient. The simultaneous ﬁ  nding of both the macrolide-
resistant (A2063G) and the macrolide-sensitive (A2063A) 
M. pneumoniae genotype in at least 1 sample from our 
propositus patient while he was receiving treatment 
suggests that the A2063G mutation may have evolved 
de novo during therapy with azithromycin. A similar 
phenomenon was observed recently in the closely related 
pathogen M. genitalium (13). Additionally, it was shown 
previously that exposing M. pneumoniae to sublethal 
concentrations of macrolides such as azithromycin can 
lead to de novo occurrence of macrolide resistance with 
A2063G mutations (14). This ﬁ  nding might suggest that 
lower concentrations of azithromycin on mucosal surfaces 
could lead to the induction of macrolide resistance in 
mycoplasmas. The phenomenon of a mixed population 
is unusual in M. pneumoniae–infected patients; analysis 
of the P1 gene of 102 M. pneumoniae isolates, including 
those obtained during epidemics (15), did not show such a 
phenomenon. Still, the infecting M. pneumoniae population 
may have been a mixture of both A2063A and A2063G 
species, which was later dominated by the resistant species. 
The occurrence of this phenomenon should be studied 
further in the community to evaluate its distribution and 
clarify whether it is related to the occurrence of de novo 
mutation or mixed infections. 
Our study emphasizes again the therapeutic challenge 
in pediatric patients with M. pneumoniae–associated 
infections whose illlnesses do not respond to macrolide 
treatment. In such cases, we suggest that quinolones 
be considered as alternative therapy, although they are 
currently not approved for this indication in the pediatric 
populations. 
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Concurrent conditions‡  4 2
Prior antibiotic use  9 6
Prior macrolide use  3 2
*Values are no. patients except as indicated. Clinical data were not available for 2 patients. 
†Two patients had Stevens-Johnson syndrome, and Still’s disease developed in 1 patient. 
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From either the Carib yaya, for sore or lesion, or yaw, an African word for berry. Th  e  term 
yaws was in common use by the 17th Century, when Dutch physician Willem Piso provided 
one of the earliest recorded descriptions of yaws in South America in De medicina Brasiliense 
in 1648. Because lesions associated with the disease resemble berries, another common name 
for yaws is frambesia tropica, from the French framboise, meaning raspberry.
Sources:  Harper D. Online etymology dictionary. Yaws [cited 2011 Apr 7]. http://www.etymonline.com/index.php?search=yaws&
searchmode=none; Book notice. Opuscula selecta Neerlandicorum de arte medica [in Dutch]. JAMA.  1937;109:1225 [cited 2011 
Apr 7]. http://jama.ama-assn.org/content/109/15/1224.4.full.pdf+html 